irinotecan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, topoisomerase I inhibitors 1482 97682-44-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • irinotecan liposome injection
  • onivyde
  • irinotecan liposome
  • irinotecan
  • irinotecan hydrochloride
  • irinotecan hydrochloride hydrate
  • irinotecan hydrochloride trihydrate
  • irinotecan HCl
Irinotecan is a derivative of camptothecin. Camptothecins act as specific inhibitors of the enzyme DNA topoisomerase I. Irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase I-DNA complex and induce single-strand DNA lesions which block the DNA replication fork and are responsible for the cytotoxicity. Irinotecan is metabolized by carboxylesterase to SN-38. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumour cell lines.
  • Molecular weight: 586.69
  • Formula: C33H38N4O6
  • CLOGP: 2.43
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 1
  • TPSA: 112.51
  • ALOGS: -3.74
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 16.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.75 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 8 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.51 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 14, 1996 FDA PFIZER INC
March 25, 2020 PMDA Nihon Servier Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 797.70 19.15 1375 30068 558227 46096392
Neutropenia 765.84 19.15 688 30755 142516 46512103
Disease progression 635.76 19.15 511 30932 90789 46563830
Mucosal inflammation 257.65 19.15 212 31231 38764 46615855
Neuropathy peripheral 253.45 19.15 309 31134 90584 46564035
Vomiting 248.82 19.15 767 30676 452027 46202592
Febrile neutropenia 248.28 19.15 312 31131 94315 46560304
Malignant neoplasm progression 244.41 19.15 258 31185 64668 46589951
Dermatitis acneiform 230.59 19.15 91 31352 3979 46650640
Bone marrow failure 214.31 19.15 170 31273 29499 46625120
Stomatitis 206.41 19.15 242 31201 68055 46586564
Leukopenia 202.96 19.15 240 31203 68103 46586516
Thrombocytopenia 194.75 19.15 324 31119 126257 46528362
Palmar-plantar erythrodysaesthesia syndrome 184.86 19.15 134 31309 20317 46634302
Neurotoxicity 174.37 19.15 111 31332 13606 46641013
Colorectal cancer metastatic 168.49 19.15 47 31396 673 46653946
Metastases to liver 160.55 19.15 121 31322 19464 46635155
Dehydration 158.81 19.15 339 31104 159201 46495418
Abdominal pain 153.92 19.15 419 31024 229612 46425007
Dysarthria 148.13 19.15 153 31290 37345 46617274
Neutrophil count decreased 146.56 19.15 163 31280 43263 46611356
Proteinuria 128.47 19.15 99 31344 16454 46638165
Decreased appetite 127.48 19.15 351 31092 193485 46461134
Off label use 126.66 19.15 548 30895 379293 46275326
Nausea 125.67 19.15 840 30603 686614 45968005
Haematotoxicity 124.26 19.15 70 31373 6863 46647756
Myelosuppression 120.02 19.15 71 31372 7632 46646987
Neoplasm progression 116.58 19.15 115 31328 26568 46628051
Peripheral sensory neuropathy 108.51 19.15 63 31380 6540 46648079
Polyneuropathy 104.53 19.15 76 31367 11568 46643051
Arthralgia 102.98 19.15 59 31384 364544 46290075
Ascites 102.80 19.15 125 31318 36459 46618160
Drug ineffective 102.00 19.15 189 31254 677649 45976970
Colon cancer 100.69 19.15 68 31375 9201 46645418
Skin toxicity 100.07 19.15 49 31394 3605 46651014
Joint swelling 98.18 19.15 3 31440 166070 46488549
Gastrointestinal toxicity 97.88 19.15 51 31392 4280 46650339
Product dose omission issue 93.07 19.15 5 31438 168515 46486104
Paronychia 92.54 19.15 50 31393 4516 46650103
Metastases to lung 89.68 19.15 67 31376 10629 46643990
Pulmonary embolism 89.22 19.15 214 31229 108371 46546248
General physical health deterioration 88.59 19.15 222 31221 115547 46539072
Cholinergic syndrome 85.06 19.15 24 31419 359 46654260
Intestinal obstruction 84.73 19.15 96 31347 25979 46628640
Ileus 83.57 19.15 72 31371 13992 46640627
Peripheral swelling 80.57 19.15 7 31436 158064 46496555
Death 75.89 19.15 434 31009 335114 46319505
Drug hypersensitivity 70.85 19.15 38 31405 243787 46410832
Colon cancer metastatic 68.12 19.15 27 31416 1193 46653426
Colorectal cancer 67.36 19.15 25 31418 922 46653697
Anaemia 66.65 19.15 344 31099 255435 46399184
Mucosal toxicity 65.80 19.15 19 31424 310 46654309
Metastases to peritoneum 65.09 19.15 33 31410 2615 46652004
Asthenia 63.00 19.15 391 31052 310684 46343935
Sinusitis 62.83 19.15 7 31436 129761 46524858
Cholangitis 62.32 19.15 39 31404 4635 46649984
Hypertension 61.88 19.15 279 31164 196077 46458542
Pain in extremity 60.81 19.15 51 31392 258629 46395990
Exposure during pregnancy 60.39 19.15 3 31440 108209 46546410
Weight increased 60.20 19.15 18 31425 164455 46490164
Intestinal perforation 59.35 19.15 53 31390 10798 46643821
Carcinoembryonic antigen increased 57.74 19.15 25 31418 1384 46653235
Laryngospasm 56.94 19.15 31 31412 2842 46651777
Gastrointestinal perforation 56.16 19.15 32 31411 3205 46651414
Enterocutaneous fistula 54.65 19.15 23 31420 1187 46653432
Fall 53.58 19.15 87 31356 329010 46325609
Hypomagnesaemia 53.03 19.15 70 31373 22140 46632479
Pain 52.99 19.15 156 31287 476792 46177827
Nephroblastoma 52.50 19.15 13 31430 113 46654506
Protein urine 49.94 19.15 18 31425 610 46654009
Cough 49.80 19.15 49 31394 230200 46424419
Hyperammonaemia 49.79 19.15 34 31409 4682 46649937
Maternal exposure during pregnancy 48.47 19.15 6 31437 102543 46552076
Headache 47.84 19.15 164 31279 478188 46176431
Steatohepatitis 46.89 19.15 16 31427 460 46654159
Asthma 46.77 19.15 4 31439 91538 46563081
White blood cell count decreased 45.98 19.15 173 31270 112058 46542561
Female genital tract fistula 45.65 19.15 28 31415 3211 46651408
Speech disorder 45.65 19.15 85 31358 36082 46618537
Pyrexia 45.07 19.15 394 31049 348408 46306211
Adenocarcinoma of colon 44.95 19.15 24 31419 2116 46652503
Metastases to meninges 44.43 19.15 23 31420 1904 46652715
Musculoskeletal stiffness 43.35 19.15 7 31436 97986 46556633
Cystitis radiation 43.34 19.15 10 31433 62 46654557
Posterior reversible encephalopathy syndrome 42.94 19.15 52 31391 15089 46639530
Arthropathy 42.46 19.15 4 31439 84696 46569923
Device related infection 42.25 19.15 61 31382 20980 46633639
Insomnia 41.91 19.15 30 31413 164894 46489725
Nasopharyngitis 41.84 19.15 26 31417 153972 46500647
Bladder tamponade 41.81 19.15 10 31433 74 46654545
Epistaxis 41.68 19.15 116 31327 64189 46590430
Depression 40.60 19.15 33 31410 170071 46484548
Feeling abnormal 40.09 19.15 17 31426 125043 46529576
Neuromyotonia 39.70 19.15 9 31434 51 46654568
Metastases to lymph nodes 39.50 19.15 34 31409 6597 46648022
Contraindicated product administered 39.49 19.15 4 31439 79943 46574676
Proctalgia 37.89 19.15 29 31414 4767 46649852
Arthritis 37.84 19.15 4 31439 77312 46577307
Venous pressure jugular decreased 37.58 19.15 8 31435 32 46654587
Bronchitis 36.29 19.15 13 31430 105966 46548653
Nasal septum perforation 36.20 19.15 15 31428 744 46653875
Condition aggravated 36.02 19.15 69 31374 244983 46409636
Tongue oedema 35.61 19.15 26 31417 3980 46650639
Large intestine perforation 35.59 19.15 34 31409 7546 46647073
Swelling 35.26 19.15 20 31423 124491 46530128
Abdominal discomfort 35.23 19.15 30 31413 151135 46503484
Enteritis 34.99 19.15 32 31411 6723 46647896
Drug interaction 34.61 19.15 52 31391 203042 46451577
Hypertensive crisis 34.19 19.15 44 31399 13571 46641048
Therapeutic product effect decreased 34.16 19.15 7 31436 82594 46572025
Skin fissures 33.34 19.15 33 31410 7647 46646972
Immune thrombocytopenia 33.19 19.15 34 31409 8207 46646412
Hypokalaemia 33.03 19.15 132 31311 87892 46566727
Influenza 32.23 19.15 10 31433 89260 46565359
Rectal cancer recurrent 31.95 19.15 7 31436 33 46654586
Trichomegaly 31.78 19.15 7 31436 34 46654585
Myalgia 31.77 19.15 22 31421 123066 46531553
Ganglioneuroma 31.51 19.15 9 31434 141 46654478
Vena cava thrombosis 31.13 19.15 19 31424 2160 46652459
Desmoplastic small round cell tumour 30.94 19.15 9 31434 151 46654468
Anxiety 29.65 19.15 48 31395 181909 46472710
Hydronephrosis 28.67 19.15 32 31411 8513 46646106
Malignant glioma 28.60 19.15 6 31437 22 46654597
Cardiac failure congestive 28.57 19.15 13 31430 91737 46562882
Aortic intramural haematoma 28.46 19.15 7 31436 59 46654560
Small intestinal obstruction 28.34 19.15 44 31399 16128 46638491
Chronic obstructive pulmonary disease 28.16 19.15 3 31440 57630 46596989
Oesophagitis 28.02 19.15 40 31403 13611 46641008
Interstitial lung disease 28.01 19.15 90 31353 53859 46600760
Gait disturbance 27.96 19.15 34 31409 145229 46509390
Pancytopenia 27.58 19.15 122 31321 84936 46569683
Sepsis 27.44 19.15 171 31272 135843 46518776
Stomatitis haemorrhagic 27.43 19.15 6 31437 28 46654591
Dizziness 26.83 19.15 128 31315 340286 46314333
Drug intolerance 26.67 19.15 36 31407 147013 46507606
Metastases to central nervous system 26.22 19.15 35 31408 11186 46643433
Wrong technique in product usage process 26.16 19.15 3 31440 54419 46600200
Tumour necrosis 26.15 19.15 12 31431 763 46653856
Neutropenic sepsis 25.13 19.15 36 31407 12288 46642331
Catheter site bruise 24.94 19.15 9 31434 306 46654313
Tumour ulceration 24.03 19.15 7 31436 118 46654501
Aortitis 23.78 19.15 11 31432 712 46653907
Venous thrombosis 23.58 19.15 22 31421 4740 46649879
Gastrointestinal stoma complication 23.30 19.15 14 31429 1547 46653072
Product use in unapproved indication 23.13 19.15 121 31322 90152 46564467
Gastric perforation 22.93 19.15 13 31430 1289 46653330
Cutaneous tuberculosis 22.86 19.15 7 31436 141 46654478
Superior vena cava syndrome 22.74 19.15 10 31433 575 46654044
Rectal perforation 22.70 19.15 9 31434 398 46654221
Metastases to abdominal cavity 22.49 19.15 9 31434 408 46654211
Palpitations 22.07 19.15 19 31424 95240 46559379
Fluid retention 21.79 19.15 4 31439 51042 46603577
Product use issue 21.78 19.15 19 31424 94625 46559994
Intentional product misuse 21.68 19.15 3 31440 47125 46607494
Influenza like illness 21.60 19.15 6 31437 57564 46597055
Rectal cancer 21.03 19.15 14 31429 1848 46652771
Stress cardiomyopathy 20.88 19.15 26 31417 7758 46646861
Paraesthesia 20.85 19.15 143 31300 117294 46537325
Liver abscess 20.83 19.15 16 31427 2643 46651976
Incorrect dose administered 20.72 19.15 3 31440 45547 46609072
Cardiotoxicity 20.56 19.15 24 31419 6698 46647921
Deep vein thrombosis 20.49 19.15 107 31336 79666 46574953
Pneumothorax spontaneous 20.39 19.15 9 31434 522 46654097
Pneumatosis intestinalis 19.97 19.15 14 31429 2011 46652608
Hypocapnia 19.94 19.15 8 31435 365 46654254
Cardiac myxoma 19.92 19.15 7 31436 220 46654399
Metastasis 19.60 19.15 19 31424 4293 46650326
Diaphragmatic paralysis 19.57 19.15 9 31434 575 46654044
Chills 19.52 19.15 121 31322 95911 46558708
Anorectal disorder 19.44 19.15 12 31431 1392 46653227
Duodenal obstruction 19.43 19.15 7 31436 237 46654382
Tongue disorder 19.21 19.15 24 31419 7186 46647433
Renal hydrocele 19.21 19.15 4 31439 14 46654605
Diabetes mellitus 19.19 19.15 5 31438 50060 46604559
Dysaesthesia pharynx 19.19 19.15 6 31437 130 46654489

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1322.38 16.61 2039 43695 332064 29574680
Disease progression 782.91 16.61 774 44960 79100 29827644
Neutropenia 708.05 16.61 923 44811 127617 29779127
Dermatitis acneiform 445.84 16.61 203 45531 5486 29901258
Stomatitis 378.70 16.61 369 45365 36910 29869834
Palmar-plantar erythrodysaesthesia syndrome 309.61 16.61 223 45511 14647 29892097
Neuropathy peripheral 308.51 16.61 454 45280 70021 29836723
Decreased appetite 265.61 16.61 656 45078 149254 29757490
Vomiting 259.82 16.61 830 44904 218988 29687756
Skin toxicity 245.31 16.61 113 45621 3136 29903608
Mucosal inflammation 244.66 16.61 266 45468 30228 29876516
Metastases to liver 243.50 16.61 177 45557 11788 29894956
Colorectal cancer metastatic 242.11 16.61 81 45653 921 29905823
Alopecia 238.38 16.61 213 45521 19062 29887682
Nausea 218.66 16.61 963 44771 295994 29610750
Proteinuria 196.83 16.61 177 45557 15968 29890776
Neoplasm progression 195.30 16.61 185 45549 17838 29888906
Colorectal cancer 193.40 16.61 80 45654 1699 29905045
Febrile neutropenia 187.68 16.61 466 45268 106227 29800517
Interstitial lung disease 180.52 16.61 327 45407 59870 29846874
Leukopenia 178.58 16.61 313 45421 55846 29850898
Myelosuppression 173.74 16.61 119 45615 7203 29899541
Cholinergic syndrome 172.52 16.61 53 45681 447 29906297
Gastrointestinal toxicity 171.11 16.61 76 45658 1932 29904812
Paronychia 161.81 16.61 83 45651 2928 29903816
Bone marrow failure 161.67 16.61 213 45521 29572 29877172
Intestinal obstruction 154.74 16.61 168 45566 19044 29887700
Malignant neoplasm progression 153.48 16.61 340 45394 71947 29834797
Dehydration 153.21 16.61 475 45259 123064 29783680
Metastases to lung 149.82 16.61 112 45622 7783 29898961
Neutrophil count decreased 135.40 16.61 237 45497 42217 29864527
Drug interaction 130.89 16.61 71 45663 199497 29707247
Completed suicide 130.08 16.61 5 45729 99487 29807257
Ileus 128.72 16.61 138 45596 15417 29891327
Off label use 125.39 16.61 727 45007 248563 29658181
Neurotoxicity 125.36 16.61 126 45608 13056 29893688
Drug ineffective 115.98 16.61 215 45519 340172 29566572
General physical health deterioration 113.50 16.61 373 45361 99571 29807173
Haematotoxicity 111.46 16.61 85 45649 6085 29900659
Pulmonary embolism 110.56 16.61 315 45419 77820 29828924
Abdominal pain 107.72 16.61 451 45283 135203 29771541
Peripheral sensory neuropathy 101.58 16.61 79 45655 5822 29900922
Carcinoembryonic antigen increased 97.89 16.61 37 45697 613 29906131
Fall 94.88 16.61 83 45651 181789 29724955
Necrotising fasciitis 88.86 16.61 59 45675 3390 29903354
Product dose omission issue 85.16 16.61 18 45716 91613 29815131
Thrombocytopenia 84.48 16.61 423 45311 136621 29770123
Colon cancer metastatic 83.52 16.61 44 45690 1641 29905103
Epistaxis 82.22 16.61 221 45513 52760 29853984
Skin reaction 80.99 16.61 62 45672 4463 29902281
Hypomagnesaemia 78.37 16.61 111 45623 16487 29890257
Colon cancer 77.72 16.61 79 45655 8293 29898451
Hiccups 73.33 16.61 81 45653 9353 29897391
Cholangitis 71.29 16.61 73 45661 7729 29899015
Intestinal perforation 71.21 16.61 76 45658 8443 29898301
Plasma cell myeloma 68.79 16.61 3 45731 53459 29853285
Headache 68.43 16.61 108 45626 182198 29724546
Cardiac failure congestive 68.11 16.61 22 45712 84385 29822359
Arthralgia 66.01 16.61 66 45668 135725 29771019
Gastrointestinal perforation 65.71 16.61 50 45684 3566 29903178
Myocardial infarction 64.64 16.61 58 45676 125567 29781177
Small intestinal obstruction 63.97 16.61 91 45643 13568 29893176
Anastomotic complication 62.32 16.61 22 45712 297 29906447
Rhabdomyolysis 62.21 16.61 11 45723 63569 29843175
Rectal cancer 57.94 16.61 38 45696 2138 29904606
Myalgia 55.13 16.61 24 45710 76643 29830101
Toxicity to various agents 54.89 16.61 118 45616 177065 29729679
Anxiety 53.16 16.61 36 45698 89835 29816909
Bradycardia 52.99 16.61 17 45717 65509 29841235
Polyneuropathy 51.34 16.61 76 45658 11747 29894997
Proteus infection 50.60 16.61 24 45710 712 29906032
Acne 50.41 16.61 67 45667 9369 29897375
Hospitalisation 49.69 16.61 5 45729 44314 29862430
Hypokalaemia 48.75 16.61 178 45556 50014 29856730
Tumour marker increased 48.62 16.61 21 45713 498 29906246
Small intestinal perforation 48.51 16.61 31 45703 1668 29905076
Weight increased 48.49 16.61 27 45707 74886 29831858
Coronary artery disease 47.76 16.61 9 45725 49703 29857041
Ileal perforation 47.53 16.61 23 45711 714 29906030
Agitation 47.47 16.61 12 45722 54061 29852683
Nicotinic acid deficiency 47.33 16.61 13 45721 70 29906674
Pneumonia 46.79 16.61 309 45425 333997 29572747
Large intestine perforation 46.64 16.61 58 45676 7593 29899151
Asthenia 46.43 16.61 529 45205 220761 29685983
Colitis microscopic 45.98 16.61 30 45704 1673 29905071
Metastases to lymph nodes 45.31 16.61 42 45692 3935 29902809
Blood alkaline phosphatase abnormal 44.40 16.61 19 45715 440 29906304
Tumour necrosis 44.34 16.61 25 45709 1068 29905676
Hypertension 44.26 16.61 327 45407 121027 29785717
Carbohydrate antigen 19-9 increased 43.87 16.61 15 45719 183 29906561
Subclavian vein thrombosis 43.67 16.61 23 45711 857 29905887
Anal haemorrhage 43.36 16.61 29 45705 1686 29905058
Blood glucose increased 43.07 16.61 20 45714 61510 29845234
Stoma site haemorrhage 42.62 16.61 23 45711 901 29905843
Somnolence 42.60 16.61 51 45683 96712 29810032
Hyperammonaemia 42.22 16.61 47 45687 5473 29901271
Subileus 41.92 16.61 36 45698 3051 29903693
Enteritis 41.52 16.61 51 45683 6594 29900150
Metastases to peritoneum 40.99 16.61 27 45707 1530 29905214
Depression 40.52 16.61 47 45687 90390 29816354
Peritonitis 40.26 16.61 96 45638 21279 29885465
Cardiac arrest 39.75 16.61 50 45684 92800 29813944
Pain in extremity 39.70 16.61 67 45667 110154 29796590
Hallucination 39.18 16.61 13 45721 49046 29857698
Feeling abnormal 38.88 16.61 19 45715 56737 29850007
Large intestinal obstruction 38.30 16.61 25 45709 1395 29905349
Asthma 38.25 16.61 5 45729 36169 29870575
Suicidal ideation 38.17 16.61 5 45729 36109 29870635
Ascites 37.97 16.61 131 45603 35790 29870954
Acral peeling skin syndrome 37.70 16.61 10 45724 46 29906698
Mouth ulceration 37.44 16.61 62 45672 10547 29896197
Dizziness 36.07 16.61 164 45570 194745 29711999
Confusional state 36.01 16.61 97 45637 134737 29772007
Abdominal pain lower 35.98 16.61 55 45679 8743 29898001
Induration 35.87 16.61 20 45714 836 29905908
White blood cell count decreased 35.75 16.61 235 45499 83712 29823032
Dysphonia 35.32 16.61 85 45649 18947 29887797
Pulmonary artery thrombosis 34.90 16.61 18 45716 642 29906102
Anaemia of malignant disease 34.89 16.61 16 45718 439 29906305
Fatigue 34.71 16.61 684 45050 319989 29586755
Transdifferentiation of neoplasm 34.55 16.61 10 45724 67 29906677
Arteriospasm coronary 34.47 16.61 30 45704 2588 29904156
Colon cancer recurrent 34.41 16.61 11 45723 107 29906637
Peripheral swelling 34.10 16.61 26 45708 61048 29845696
Rash pustular 34.01 16.61 40 45694 4943 29901801
Failure to anastomose 33.05 16.61 13 45721 241 29906503
Neutropenic sepsis 32.89 16.61 61 45673 11348 29895396
Conjunctivitis 32.70 16.61 50 45684 7950 29898794
Metastases to pelvis 32.66 16.61 13 45721 249 29906495
Catheter site thrombosis 32.12 16.61 8 45726 27 29906717
Influenza 32.12 16.61 13 45721 43385 29863359
Vena cava thrombosis 31.94 16.61 20 45714 1038 29905706
Tumour haemorrhage 31.35 16.61 28 45706 2500 29904244
Wheezing 31.03 16.61 5 45729 30933 29875811
Insomnia 30.68 16.61 60 45674 93276 29813468
Overdose 30.60 16.61 51 45683 84286 29822458
Pyrexia 30.46 16.61 624 45110 293865 29612879
Adenocarcinoma of colon 30.43 16.61 31 45703 3261 29903483
Joint swelling 30.25 16.61 17 45717 46929 29859815
Unevaluable event 30.01 16.61 6 45728 31779 29874965
Prothrombin level decreased 29.91 16.61 20 45714 1162 29905582
Toxic erythema of chemotherapy 29.45 16.61 8 45726 41 29906703
Therapy partial responder 29.22 16.61 32 45702 3659 29903085
Wrong technique in product usage process 29.17 16.61 6 45728 31149 29875595
Acute abdomen 28.95 16.61 23 45711 1748 29904996
Leukoencephalopathy 28.77 16.61 33 45701 3969 29902775
Balance disorder 28.57 16.61 10 45724 36483 29870261
Dyspnoea 28.55 16.61 349 45385 332946 29573798
Perforation bile duct 27.98 16.61 8 45726 51 29906693
Incorrect dose administered 27.87 16.61 7 45727 31679 29875065
Venous thrombosis 27.28 16.61 29 45705 3205 29903539
Malignant ascites 27.03 16.61 13 45721 398 29906346
Hypoglycaemia 26.83 16.61 23 45711 50958 29855786
Metastasis 26.81 16.61 29 45705 3269 29903475
Anal fissure 26.75 16.61 25 45709 2366 29904378
Rectal cancer metastatic 26.66 16.61 11 45723 232 29906512
Perioral dermatitis 26.61 16.61 9 45725 106 29906638
Hyperbilirubinaemia 26.58 16.61 71 45663 16871 29889873
Clostridial infection 26.25 16.61 30 45704 3595 29903149
Loss of consciousness 26.11 16.61 51 45683 79324 29827420
Tremor 26.04 16.61 47 45687 75316 29831428
Abnormal behaviour 26.02 16.61 4 45730 25619 29881125
Pruritus 25.91 16.61 93 45641 118111 29788633
Pelvic fluid collection 25.73 16.61 9 45725 118 29906626
Stoma site pain 25.34 16.61 15 45719 703 29906041
Tumour perforation 25.04 16.61 11 45723 272 29906472
Nail disorder 24.82 16.61 21 45713 1744 29905000
Constipation 24.54 16.61 272 45462 112634 29794110
Lymphangiosis carcinomatosa 24.51 16.61 16 45718 893 29905851
Vascular pseudoaneurysm 24.50 16.61 22 45712 1978 29904766
Device related infection 24.40 16.61 69 45665 16946 29889798
Deep vein thrombosis 24.32 16.61 167 45567 60334 29846410
Perihepatic abscess 24.06 16.61 8 45726 89 29906655
Chronic obstructive pulmonary disease 24.04 16.61 21 45713 46105 29860639
Chronic kidney disease 23.95 16.61 14 45720 37824 29868920
Product use issue 23.93 16.61 21 45713 45995 29860749
Pelvic abscess 23.83 16.61 16 45718 936 29905808
Liver abscess 23.62 16.61 27 45707 3235 29903509
Disturbance in attention 23.53 16.61 3 45731 22126 29884618
Proctalgia 23.28 16.61 31 45703 4341 29902403
Superior vena cava syndrome 23.24 16.61 12 45722 429 29906315
Anaemia 23.22 16.61 446 45288 207546 29699198
Memory impairment 23.18 16.61 14 45720 37160 29869584
Unresponsive to stimuli 22.92 16.61 6 45728 26413 29880331
Change of bowel habit 22.88 16.61 16 45718 1001 29905743
Therapeutic product effect decreased 22.70 16.61 8 45726 29068 29877676
Adverse drug reaction 22.64 16.61 4 45730 23141 29883603
Performance status decreased 22.54 16.61 29 45705 3928 29902816
Peritoneal haematoma 22.38 16.61 7 45727 63 29906681
Epidermal naevus syndrome 22.30 16.61 5 45729 9 29906735
Cardiac disorder 22.24 16.61 17 45717 39876 29866868
Intestinal strangulation 22.21 16.61 6 45728 30 29906714
Contusion 22.14 16.61 10 45724 31270 29875474
Dry skin 22.09 16.61 80 45654 22374 29884370
Pancreatic carcinoma metastatic 22.05 16.61 26 45708 3221 29903523
Influenza like illness 21.86 16.61 6 45728 25599 29881145
Obstruction gastric 21.67 16.61 15 45719 923 29905821
Electrocardiogram QT prolonged 21.65 16.61 14 45720 35821 29870923
Hypovolaemic shock 21.62 16.61 37 45697 6463 29900281
Chronic myeloid leukaemia 21.55 16.61 23 45711 2554 29904190
Acute cutaneous lupus erythematosus 21.55 16.61 7 45727 72 29906672
Cough 21.30 16.61 109 45625 125533 29781211
Pelvic venous thrombosis 21.17 16.61 12 45722 518 29906226
Protein urine 21.13 16.61 13 45721 654 29906090
Fluid retention 21.08 16.61 6 45728 24992 29881752
Disseminated intravascular coagulation 20.98 16.61 78 45656 22093 29884651
Fistula 20.91 16.61 32 45702 5090 29901654
Stomal varices 20.76 16.61 6 45728 40 29906704
Oesophagobronchial fistula 20.71 16.61 8 45726 141 29906603
Portal vein thrombosis 20.70 16.61 26 45708 3438 29903306
Lactic acidosis 20.55 16.61 11 45723 31202 29875542
Irritability 20.45 16.61 5 45729 23045 29883699
Abdominal pain upper 20.23 16.61 164 45570 62387 29844357
Cellulitis 20.21 16.61 25 45709 46759 29859985
Septic shock 20.15 16.61 166 45568 63441 29843303
Paraesthesia 20.11 16.61 147 45587 54180 29852564
Colonic fistula 20.07 16.61 10 45724 331 29906413
Klebsiella infection 20.07 16.61 37 45697 6850 29899894
Enterocutaneous fistula 20.02 16.61 13 45721 719 29906025
Treatment noncompliance 19.63 16.61 7 45727 25246 29881498
Colony stimulating factor therapy 19.55 16.61 8 45726 165 29906579
VIth nerve disorder 19.41 16.61 5 45729 20 29906724
Fistula of small intestine 19.25 16.61 10 45724 362 29906382
International normalised ratio increased 19.10 16.61 27 45707 47712 29859032
Limbic encephalitis 19.04 16.61 9 45725 265 29906479
Hypoalbuminaemia 18.95 16.61 48 45686 11044 29895700
Device related thrombosis 18.84 16.61 13 45721 796 29905948
Cardiotoxicity 18.62 16.61 28 45706 4386 29902358
Arthritis 18.56 16.61 7 45727 24394 29882350
Diabetes mellitus 18.48 16.61 22 45712 41843 29864901
Portal hypertension 18.42 16.61 26 45708 3847 29902897
Enterocolitis 18.34 16.61 35 45699 6652 29900092
Delirium 18.31 16.61 21 45713 40610 29866134
Accidental overdose 18.22 16.61 3 45731 18272 29888472
Hyperammonaemic encephalopathy 18.21 16.61 18 45716 1826 29904918
Rectal tenesmus 18.19 16.61 11 45723 536 29906208
Medulloblastoma 18.11 16.61 6 45728 66 29906678
Glioblastoma multiforme 18.08 16.61 13 45721 850 29905894
Bile duct stenosis 18.04 16.61 15 45719 1216 29905528
Serotonin syndrome 17.70 16.61 3 45731 17888 29888856
Sinusitis 17.60 16.61 15 45719 33330 29873414
Skin disorder 17.56 16.61 48 45686 11560 29895184
Heart rate increased 17.46 16.61 20 45714 38701 29868043
Hepatic failure 17.44 16.61 100 45634 33943 29872801
Venoocclusive liver disease 17.38 16.61 34 45700 6579 29900165
Peripheral sensorimotor neuropathy 17.37 16.61 15 45719 1280 29905464
Mechanical ileus 17.36 16.61 8 45726 222 29906522
Mobility decreased 17.35 16.61 9 45725 25990 29880754
Nodular regenerative hyperplasia 17.28 16.61 12 45722 742 29906002
Genital herpes zoster 16.95 16.61 4 45730 10 29906734
Product quality issue 16.80 16.61 4 45730 18770 29887974
Oesophagitis 16.70 16.61 46 45688 11125 29895619
Fingerprint loss 16.62 16.61 5 45729 39 29906705

Pharmacologic Action:

SourceCodeDescription
ATC L01CE02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Topoisomerase 1 (TOP1) inhibitors
FDA MoA N0000000176 Topoisomerase Inhibitors
FDA EPC N0000175609 Topoisomerase Inhibitor
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:50266 prodrugs
CHEBI has role CHEBI:50276 topoisomerase i inhibitors
CHEBI has role CHEBI:68495 type i programmed cell-death inducer
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059004 Topoisomerase I Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Secondary malignant neoplasm of pancreas indication 94459006
Metastasis from malignant tumor of colon indication 314998002
Adenocarcinoma of pancreas indication 700423003 DOID:4074
Astrocytoma, anaplastic off-label use 55353007 DOID:3078
Ewing's sarcoma off-label use 76909002 DOID:3369
Small cell carcinoma of lung off-label use 254632001 DOID:5409
Non-small cell lung cancer off-label use 254637007 DOID:3908
Glioblastoma multiforme of brain off-label use 276828006 DOID:3073
Hyperbilirubinemia contraindication 14783006 DOID:2741
Dehydration contraindication 34095006
Diarrhea contraindication 62315008
Interstitial pneumonia contraindication 64667001
Intestinal obstruction contraindication 81060008 DOID:8437
Kidney disease contraindication 90708001 DOID:557
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Sepsis syndrome contraindication 238150007
Renal dialysis contraindication 265764009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Thromboembolic disorder contraindication 371039008
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
UGT1A1*28 polymorphism contraindication 430235005

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.46 acidic
pKa2 9.25 Basic
pKa3 2.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) ONIVYDE IPSEN INC N207793 Oct. 22, 2015 RX INJECTABLE, LIPOSOMAL INTRAVENOUS Oct. 22, 2022 FOR USE IN COMBINULLTION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 1 Enzyme INHIBITOR DRUGBANK CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 6.66 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 6.34 DRUG MATRIX
Interstitial collagenase Enzyme IC50 5.22 DRUG MATRIX
Multidrug resistance-associated protein 4 Transporter WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance protein 1 Transporter WOMBAT-PK
Solute carrier family 22 member 3 Transporter IC50 4.13 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.68 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.57 CHEMBL
Acetylcholinesterase Enzyme Ki 7.30 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 5.10 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.68 CHEMBL
Acetylcholinesterase Enzyme Ki 7.58 CHEMBL

External reference:

IDSource
4024027 VUID
N0000022032 NUI
D01061 KEGG_DRUG
136572-09-3 SECONDARY_CAS_RN
4020969 VANDF
4024027 VANDF
C0123931 UMLSCUI
CHEBI:80630 CHEBI
CP0 PDB_CHEM_ID
CHEMBL481 ChEMBL_ID
CHEMBL541887 ChEMBL_ID
CHEMBL1200512 ChEMBL_ID
CHEMBL3989514 ChEMBL_ID
DB00762 DRUGBANK_ID
D000077146 MESH_DESCRIPTOR_UI
6823 IUPHAR_LIGAND_ID
6694 INN_ID
7673326042 UNII
60838 PUBCHEM_CID
153329 RXNORM
12129 MMSL
236647 MMSL
4918 MMSL
81265 MMSL
d04026 MMSL
d08389 MMSL
005262 NDDF
005263 NDDF
108783005 SNOMEDCT_US
372538008 SNOMEDCT_US
386912006 SNOMEDCT_US
715213000 SNOMEDCT_US
725861003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Camptosar HUMAN PRESCRIPTION DRUG LABEL 1 0009-7529 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 30 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9583 INJECTION 20 mg INTRAVENOUS ANDA 28 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9701 INJECTION 20 mg INTRAVENOUS ANDA 28 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9702 INJECTION 20 mg INTRAVENOUS ANDA 28 sections
Onivyde HUMAN PRESCRIPTION DRUG LABEL 1 15054-0043 INJECTION, POWDER, FOR SOLUTION 4.30 mg INTRAVENOUS NDA 29 sections
Irinotecan hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-027 INJECTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-131 INJECTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-230 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 45963-614 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 20 sections
Irinotecan hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 45963-614 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 20 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50742-401 INJECTION 40 mg INTRAVENOUS ANDA 27 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50742-402 INJECTION 100 mg INTRAVENOUS ANDA 27 sections
IRINOTECAN HYDROCHLORIDE Human Prescription Drug Label 1 55150-352 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
IRINOTECAN HYDROCHLORIDE Human Prescription Drug Label 1 55150-353 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
IRINOTECAN HYDROCHLORIDE Human Prescription Drug Label 1 55150-354 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 59923-702 INJECTION 20 mg INTRAVENOUS ANDA 26 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 59923-714 INJECTION 20 mg INTRAVENOUS ANDA 31 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 59923-715 INJECTION 20 mg INTRAVENOUS ANDA 31 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 59923-716 INJECTION 20 mg INTRAVENOUS ANDA 31 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-6128 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 61703-349 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63323-193 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 27 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 67184-0511 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 67184-0512 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 67184-0513 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68001-284 INJECTION 20 mg INTRAVENOUS ANDA 26 sections
Irinotecan Hydrochloride40 mg/2 mL HUMAN PRESCRIPTION DRUG LABEL 1 68001-425 INJECTION 20 mg INTRAVENOUS ANDA 27 sections
Irinotecan Hydrochloride100 mg/ 5 mL HUMAN PRESCRIPTION DRUG LABEL 1 68001-426 INJECTION 20 mg INTRAVENOUS ANDA 27 sections
Irinotecan hydrochloide HUMAN PRESCRIPTION DRUG LABEL 1 68001-480 INJECTION 20 mg INTRAVENOUS ANDA 29 sections
Irinotecan hydrochloide Human Prescription Drug Label 1 68083-381 INJECTION 20 mg INTRAVENOUS ANDA 29 sections